Disease state fingerprint in frontotemporal degeneration with reference to alzheimer's disease and mild cognitive impairment

Journal of Alzheimer's Disease

Volumn 35, Issue 4, 2013, Pages 727-739

  Muñoz Ruiz, Miguel Ángel ^a   Hartikainen, Päivi ^a,b   Hall, Anette ^a   Mattila, Jussi ^c   Koikkalainen, Juha ^c   Herukka, Sanna Kaisa ^a,b   Julkunen, Valtteri ^a   Vanninen, Ritva ^b   Liu, Yawu ^a,b   Lötjönen, Jyrki ^c   Soininen, Hilkka ^a,b  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b KUOPIO UNIVERSITY HOSPITAL   (Finland)

^c VTT TECHNICAL RESEARCH CENTRE OF FINLAND   (Finland)

Author keywords

Alzheimer's disease; cognition; frontotemporal dementia; memory; mild cognitive impairment

Indexed keywords

APOLIPOPROTEIN E2; APOLIPOPROTEIN E3; APOLIPOPROTEIN E4;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE STATE FINGERPRINT; DISEASE STATE INDEX; FEMALE; FRONTAL VARIANT FRONTOTEMPORAL DEMENTIA; GENOTYPE; HUMAN; MALE; MENTAL PERFORMANCE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; VOLUMETRY; VOXEL BASED MORPHOMETRY;

EID: 84878832284     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-122260     Document Type: Article

References (55)

1. Mattila J, Koikkalainen J, Virkki A, Simonsen A, van Gils M, Waldemar G, Soininen H, Lotjonen J, Alzheimer's Disease Neuroimaging, Initiative (2011) A disease state fingerprint for evaluation of Alzheimer's disease. J Alzheimers Dis 27, 163-176.
2. Mattila J, Koikkalainen J, Virkki A, van Gils M, Lotjonen J, Alzheimer's Disease Neuroimaging, Initiative (2012) Design and application of a generic clinical decision support system for multiscale data. IEEE Trans Biomed Eng 59, 234-240.
3. Brookmeyer R, Johnson E, Ziegler-Graham K, Arrighi HM (2007) Forecasting the global burden of Alzheimer's disease. Alzheimers Dement 3, 186-191.
4. Ratnavalli E, Brayne C, Dawson K, Hodges JR (2002) The prevalence of frontotemporal dementia. Neurology 58, 1615-1621.
5. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51, 1546-1554.
6. Wolz R, Julkunen V, Koikkalainen J, Niskanen E, Zhang DP, Rueckert D, Soininen H, Lotjonen J, Alzheimer's Disease Neuroimaging, Initiative (2011) Multi-method analysis of MRI images in early diagnostics of Alzheimer's disease. PLoS One 6, e25446.
7. Ashburner J, Friston KJ (2000) Voxel-based morphometry- the methods. Neuroimage 11, 805-821.
8. Broe M, Hodges JR, Schofield E, Shepherd CE, Kril JJ, Halliday GM (2003) Staging disease severity in pathologically confirmed cases of frontotemporal dementia. Neurology 60, 1005-1011.
9. Avants B, Grossman M, Gee JC (2005) The correlation of cognitive decline with frontotemporal dementia induced annualized gray matter loss using diffeomorphic morphometry. Alzheimer Dis Assoc Disord 19(Suppl 1), S25-S28.
10. Brambati SM, Renda NC, Rankin KP, Rosen HJ, Seeley WW, Ashburner J, Weiner MW, Miller BL, Gorno-Tempini ML (2007) A tensor based morphometry study of longitudinal gray matter contraction in FTD. Neuroimage 35, 998-1003.
11. Williams GB, Nestor PJ, Hodges JR (2005) Neural correlates of semantic and behavioural deficits in frontotemporal dementia. Neuroimage 24, 1042-1051.
12. Chang JL, Lomen-Hoerth C, Murphy J, Henry RG, Kramer JH, Miller BL, Gorno-Tempini ML (2005) A voxel-based morphometry study of patterns of brain atrophy in ALS and ALS/FTLD. Neurology 65, 75-80.
13. Davies RR, Scahill VL, Graham A, Williams GB, Graham KS, Hodges JR (2009) Development of an MRI rating scale for multiple brain regions: Comparison with volumetrics and with voxel-based morphometry. Neuroradiology 51, 491-503.
14. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
15. Mattsson N, Rosen E, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek MM, Olde Rikkert M, Tsolaki M, Mulugeta E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Wallin A, Eriksdotter-Jonhagen M, Minthon L,Winblad B, Blennow K, Zetterberg H (2012) Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology 78, 468-476.
16. Hansson O, Zetterberg H, Buchhave P, Andreasson U, Londos E, Minthon L, Blennow K (2007) Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement Geriatr Cogn Disord 23, 316-320.
17. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study. Lancet Neurol 5, 228-234.
18. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid betaamyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389.
19. Seppala TT, Nerg O, Koivisto AM, Rummukainen J, Puli L, Zetterberg H, Pyykko OT, Helisalmi S, Alafuzoff I, Hiltunen M, Jaaskelainen JE, Rinne J, Soininen H, Leinonen V, Herukka SK (2012) CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology 78, 1568-1575.
20. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark CM, Rosso S, Trojanowski J, Lee VM, Grossman M (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70, 1827-1835.
21. Kapaki E, Paraskevas GP, Papageorgiou SG, Bonakis A, Kalfakis N, Zalonis I, Vassilopoulos D (2008) Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis Assoc Disord 22, 47-53.
22. de Souza LC, Lamari F, Belliard S, Jardel C, Houillier C, De Paz R, Dubois B, Sarazin M (2011) Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias. J Neurol Neurosurg Psychiatry 82, 240-246.
23. de Rino F, Martinelli-Boneschi F, Caso F, Zuffi M, Zabeo M, Passerini G, Comi G, Magnani G, Franceschi M (2011) CSF metabolites in the differential diagnosis of Alzheimer's disease from frontal variant of frontotemporal dementia. Neurol Sci 33, 973-977.
24. Schoonenboom NS, Reesink FE,Verwey NA,Kester MI, Teunissen CE, van deVen PM, Pijnenburg YA, Blankenstein MA, Rozemuller AJ, Scheltens P, van der Flier WM (2012) Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. Neurology 78, 47-54.
25. Neary D, Snowden JS, Northen B, Goulding P (1988) Dementia of frontal lobe type. J Neurol Neurosurg Psychiatry 51, 353-361.
26. Munoz-Ruiz MA, Hartikainen P, Koikkalainen J, Wolz R, Julkunen V, Niskanen E, Herukka SK, Kivipelto M, Vanninen R, Rueckert D, Liu Y, Lotjonen J, Soininen H (2012) Structural MRI in Frontotemporal dementia: Comparisons between hippocampal volumetry, tensor-based morphometry and voxel-based morphometry. PLoS One 7, e52531.
27. Agosta F, Canu E, Sarro L, Comi G, Filippi M (2012) Neuroimaging findings in frontotemporal lobar degeneration spectrum of disorders. Cortex 48, 389-413.
28. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K (2006) Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol 112, 389-404.
29. Julkunen V, Niskanen E, Koikkalainen J, Herukka SK, Pihlajamaki M, Hallikainen M, Kivipelto M, Muehlboeck S, Evans AC, Vanninen R, Hilkka S (2010) Differences in cortical thickness in healthy controls, subjects with mild cognitive impairment, and Alzheimer's disease patients: A longitudinal study. J Alzheimers Dis 21, 1141-1151.
30. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, Soininen H, Tuomilehto J, Nissinen A (2001) Midlife vascular risk factors and Alzheimer's disease in later life: Longitudinal, population based study. BMJ 322, 1447-1451.
31. Hanninen T, Hallikainen M, Tuomainen S, Vanhanen M, Soininen H (2002) Prevalence of mild cognitive impairment: A population-based study in elderly subjects. Acta Neurol Scand 106, 148-154.
32. Pennanen C, Testa C, LaaksoMP, Hallikainen M, Helkala EL, Hanninen T, Kivipelto M, Kononen M, Nissinen A, Tervo S, Vanhanen M, Vanninen R, Frisoni GB, Soininen H (2005) A voxel based morphometry study on mild cognitive impairment. J Neurol Neurosurg Psychiatry 76, 11-14.
33. Julkunen V, Niskanen E, Muehlboeck S, Pihlajamaki M, Kononen M, Hallikainen M, Kivipelto M, Tervo S, Vanninen R, Evans A, Soininen H (2009) Cortical thickness analysis to detect progressive mild cognitive impairment: A reference to Alzheimer's disease. Dement Geriatr Cogn Disord 28, 404-412.
34. Petersen RC, Smith GE, Ivnik RJ, Tangalos EG, Schaid DJ, Thibodeau SN, Kokmen E, Waring SC, Kurland LT (1995) Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 273, 1274-1278.
35. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Kokmen E, Tangelos EG (1997) Aging, memory, and mild cognitive impairment. Int Psychogeriatr 9(Suppl 1), 65-69.
36. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M,DeDeyn PP, Bancher C, Cras P,Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Vanderstichele H (1999) Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52, 1555-1562.
37. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: A prospective cohort study. Lancet Neurol 8, 619-627.
38. Lotjonen J, Wolz R, Koikkalainen J, Julkunen V, Thurfjell L, Lundqvist R, Waldemar G, Soininen H, Rueckert D, Alzheimer's Disease Neuroimaging, Initiative (2011) Fast and robust extraction of hippocampus from MR images for diagnostics of Alzheimer's disease. Neuroimage 56, 185-196.
39. Lotjonen JM, Wolz R, Koikkalainen JR, Thurfjell L, Waldemar G, Soininen H, Rueckert D, Alzheimer's Disease Neuroimaging, Initiative (2010) Fast and robust multi-atlas segmentation of brain magnetic resonance images. Neuroimage 49, 2352-2365.
40. Roses AD (1996) Apolipoprotein E alleles as risk factors in Alzheimer's disease. Annu Rev Med 47, 387-400.
41. Corder EH, Saunders AM, Risch NJ, Strittmatter WJ, Schmechel DE, Gaskell PC, Jr., Rimmler JB, Locke PA, Conneally PM, Schmader KE (1994) Protective effect of apolipoproteinEtype 2 allele for late onset Alzheimer disease. Nat Genet 7, 180-184.
42. Tsukamoto K,Watanabe T, Matsushima T, Kinoshita M, Kato H, Hashimoto Y, Kurokawa K, Teramoto T (1993) Determination by PCR-RFLP of apo E genotype in a Japanese population. J Lab Clin Med 121, 598-602.
43. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G,Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746.
44. Boutoleau-Bretonniere C, Lebouvier T, Delaroche O, Lamy E, Evrard C, Charriau T, Bretonniere C, Damier P, Derkinderen P, Vercelletto M (2012) Value of neuropsychological testing, imaging, and CSF biomarkers for the differential diagnosis and prognosis of clinically ambiguous dementia. J Alzheimers Dis 28, 323-336.
45. van de Pol LA, Hensel A, van der Flier WM, Visser PJ, Pijnenburg YA, Barkhof F, Gertz HJ, Scheltens P (2006) Hippocampal atrophy onMRI in frontotemporal lobar degeneration and Alzheimer's disease. J Neurol Neurosurg Psychiatry 77, 439-442.
46. Hutchinson AD, Mathias JL (2007) Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: A meta-analytic review. J Neurol Neurosurg Psychiatry 78, 917-928.
47. Zetterberg H, Blennow K(2013) Cerebrospinal fluid biomarkers for Alzheimer's disease: More to come? J Alzheimers Dis 33(Suppl 1), S361-S369.
48. Blennow K (2004) Cerebrospinal fluid protein biomarkers for Alzheimer's disease. NeuroRx 1, 213-225.
49. Bibl M, Mollenhauer B, Lewczuk P, Esselmann H, Wolf S, Otto M, Kornhuber J, Ruther E, Wiltfang J (2011) Cerebrospinal fluid tau, p-tau 181 and amyloid-beta38/40/42 in frontotemporal dementias and primary progressive aphasias. Dement Geriatr Cogn Disord 31, 37-44.
50. Buerger K, Teipel SJ, Zinkowski R, Blennow K, Arai H, Engel R, Hofmann-Kiefer K, McCulloch C, Ptok U, Heun R, Andreasen N, DeBernardis J, Kerkman D, Moeller H, Davies P, Hampel H (2002) CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology 59, 627-629.
51. Lovati C, Galimberti D, Albani D, Bertora P, Venturelli E, Cislaghi G, Guidi I, Fenoglio C, Cortini F, Clerici F, Finazzi D, Forloni G, Scarpini E, Mariani C (2010) APOE epsilon2 and epsilon4 influence the susceptibility for Alzheimer's disease but not other dementias. Int J Mol Epidemiol Genet 1, 193-200.
52. Borroni B, Grassi M, Archetti S, Papetti A, Del Bo R, Bonvicini C, Comi GP, Gennarelli M, Bellelli G, Di Luca M, Padovani A (2011) Genetic background predicts poor prognosis in frontotemporal lobar degeneration. Neurodegener Dis 8, 289-295.
53. Engelborghs S, Dermaut B, Goeman J, Saerens J, Marien P, Pickut BA, Van den Broeck M, Serneels S, Cruts M, Van Broeckhoven C, De Deyn PP (2003) Prospective Belgian study of neurodegenerative and vascular dementia: APOE genotype effects. J Neurol Neurosurg Psychiatry 74, 1148-1151.
54. Seripa D, Bizzarro A, Panza F, Acciarri A, Pellegrini F, Pilotto A, Masullo C (2011) The APOE gene locus in frontotemporal dementia and primary progressive aphasia. Arch Neurol 68, 622-628.
55. Chow TW, Hynan LS, Lipton AM (2006) MMSE scores decline at a greater rate in frontotemporal degeneration than in AD. Dement Geriatr Cogn Disord 22, 194-199.